Roundview Capital LLC lifted its holdings in shares of Abbott Laboratories (NYSE:ABT) by 33.6% during the 4th quarter, HoldingsChannel reports. The fund owned 8,358 shares of the healthcare product maker’s stock after buying an additional 2,103 shares during the period. Roundview Capital LLC’s holdings in Abbott Laboratories were worth $605,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of ABT. Vanguard Group Inc. increased its position in shares of Abbott Laboratories by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 139,012,321 shares of the healthcare product maker’s stock worth $10,197,944,000 after purchasing an additional 2,208,781 shares during the last quarter. Vanguard Group Inc increased its position in shares of Abbott Laboratories by 1.6% in the 3rd quarter. Vanguard Group Inc now owns 139,012,321 shares of the healthcare product maker’s stock worth $10,197,944,000 after purchasing an additional 2,208,781 shares during the last quarter. BlackRock Inc. increased its position in shares of Abbott Laboratories by 3.3% in the 4th quarter. BlackRock Inc. now owns 121,045,590 shares of the healthcare product maker’s stock worth $8,755,228,000 after purchasing an additional 3,842,101 shares during the last quarter. Oregon Public Employees Retirement Fund increased its position in shares of Abbott Laboratories by 7,559.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 30,095,862 shares of the healthcare product maker’s stock worth $416,000 after purchasing an additional 29,702,943 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Abbott Laboratories by 102,159.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 27,234,758 shares of the healthcare product maker’s stock worth $1,997,943,000 after purchasing an additional 27,208,125 shares during the last quarter. Institutional investors and hedge funds own 75.16% of the company’s stock.

Abbott Laboratories stock opened at $78.97 on Thursday. The company has a market capitalization of $138.18 billion, a price-to-earnings ratio of 27.42, a P/E/G ratio of 2.09 and a beta of 1.13. The company has a current ratio of 1.62, a quick ratio of 1.20 and a debt-to-equity ratio of 0.63. Abbott Laboratories has a twelve month low of $56.81 and a twelve month high of $80.74.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, January 23rd. The healthcare product maker reported $0.81 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.81. The firm had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.82 billion. Abbott Laboratories had a net margin of 7.74% and a return on equity of 16.55%. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.74 EPS. Equities research analysts forecast that Abbott Laboratories will post 3.2 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Shareholders of record on Monday, April 15th will be paid a $0.32 dividend. The ex-dividend date is Friday, April 12th. This represents a $1.28 annualized dividend and a yield of 1.62%. Abbott Laboratories’s dividend payout ratio is presently 44.44%.

Several equities research analysts have recently weighed in on ABT shares. Morgan Stanley boosted their target price on shares of Abbott Laboratories from $82.00 to $85.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 2nd. Citigroup lowered shares of Abbott Laboratories from a “neutral” rating to a “sell” rating and decreased their price target for the company from $72.00 to $68.00 in a report on Wednesday, January 2nd. Zacks Investment Research raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $80.00 price target for the company in a report on Monday, January 28th. Bank of America reaffirmed a “buy” rating and issued a $81.00 price target (up from $73.00) on shares of Abbott Laboratories in a report on Thursday, February 7th. Finally, Argus lifted their price target on shares of Abbott Laboratories to $90.00 and gave the company an “in-line” rating in a report on Friday, January 25th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and fifteen have given a buy rating to the stock. Abbott Laboratories presently has a consensus rating of “Buy” and a consensus price target of $80.18.

In other Abbott Laboratories news, CFO Brian B. Yoor sold 2,246 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $78.00, for a total value of $175,188.00. Following the completion of the sale, the chief financial officer now directly owns 116,627 shares of the company’s stock, valued at $9,096,906. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jared Watkin sold 1,391 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $78.00, for a total transaction of $108,498.00. Following the completion of the sale, the senior vice president now directly owns 75,926 shares of the company’s stock, valued at $5,922,228. The disclosure for this sale can be found here. In the last quarter, insiders sold 280,021 shares of company stock worth $20,485,856. Company insiders own 0.70% of the company’s stock.

WARNING: “Roundview Capital LLC Acquires 2,103 Shares of Abbott Laboratories (ABT)” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.watchlistnews.com/roundview-capital-llc-acquires-2103-shares-of-abbott-laboratories-abt/2954563.html.

Abbott Laboratories Company Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

See Also: 52-Week High/Low

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.